Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a ...

Add Yahoo as a preferred source to see more of our stories on Google. A biologist works on DNA extracted from cancer tissue in Oncompass Medicine's laboratory in Budapest, Hungary, June 2, 2021.

A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials.

Weight-loss drugs have been found to dramatically slash death rates in colon cancer patients, according to new research. Patients taking GLP-1 receptors - the class of drugs behind Ozempic, Wegovy and ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...

Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...